 Jean Mulcahy Levy
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autophagy | 8 | 2021 | 235 | 2.440 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2021 | 191 | 2.410 |
Why?
| | Brain Neoplasms | 11 | 2024 | 966 | 2.080 |
Why?
| | Glioma | 7 | 2024 | 285 | 1.800 |
Why?
| | Central Nervous System Neoplasms | 3 | 2019 | 125 | 1.550 |
Why?
| | Chloroquine | 3 | 2017 | 52 | 0.680 |
Why?
| | Transplantation, Autologous | 1 | 2019 | 175 | 0.610 |
Why?
| | Chordoma | 1 | 2017 | 10 | 0.570 |
Why?
| | Indoles | 2 | 2017 | 300 | 0.560 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 24 | 0.560 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 36 | 0.550 |
Why?
| | Sulfonamides | 2 | 2017 | 444 | 0.520 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2017 | 636 | 0.490 |
Why?
| | Epilepsy | 1 | 2018 | 278 | 0.470 |
Why?
| | Neoplasms | 2 | 2019 | 2086 | 0.420 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 283 | 0.410 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 72 | 0.400 |
Why?
| | Antineoplastic Agents | 4 | 2017 | 1875 | 0.390 |
Why?
| | Ependymoma | 3 | 2019 | 152 | 0.380 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2017 | 519 | 0.380 |
Why?
| | Mutation | 5 | 2021 | 3338 | 0.340 |
Why?
| | Survivors | 1 | 2012 | 412 | 0.320 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 179 | 0.320 |
Why?
| | RNA-Binding Proteins | 2 | 2021 | 344 | 0.290 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 2700 | 0.270 |
Why?
| | Cell Survival | 3 | 2019 | 1014 | 0.270 |
Why?
| | Cerebellar Neoplasms | 2 | 2018 | 130 | 0.250 |
Why?
| | Child | 12 | 2024 | 18401 | 0.250 |
Why?
| | Medulloblastoma | 2 | 2018 | 172 | 0.250 |
Why?
| | Humans | 27 | 2024 | 114045 | 0.240 |
Why?
| | Child, Preschool | 7 | 2021 | 9114 | 0.230 |
Why?
| | Biomarkers, Tumor | 3 | 2019 | 1032 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2015 | 172 | 0.210 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 926 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 2 | 2021 | 784 | 0.200 |
Why?
| | raf Kinases | 1 | 2021 | 10 | 0.200 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.190 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 35 | 0.190 |
Why?
| | Pituitary Diseases | 1 | 2020 | 21 | 0.180 |
Why?
| | Infant | 4 | 2019 | 7943 | 0.180 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 34 | 0.180 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 271 | 0.170 |
Why?
| | Pituitary Gland | 1 | 2020 | 147 | 0.170 |
Why?
| | Immunocompromised Host | 1 | 2021 | 192 | 0.170 |
Why?
| | Biological Assay | 2 | 2021 | 112 | 0.170 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 15 | 0.170 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2019 | 7 | 0.170 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2019 | 22 | 0.160 |
Why?
| | Aminopyridines | 1 | 2019 | 81 | 0.160 |
Why?
| | Benzamides | 1 | 2019 | 168 | 0.160 |
Why?
| | Multigene Family | 1 | 2019 | 190 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 62 | 0.150 |
Why?
| | Male | 12 | 2021 | 55396 | 0.150 |
Why?
| | Adolescent | 7 | 2021 | 17800 | 0.150 |
Why?
| | Skull Neoplasms | 1 | 2017 | 22 | 0.150 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 28 | 0.140 |
Why?
| | Rhabdomyoma | 1 | 2017 | 9 | 0.140 |
Why?
| | Angiomyolipoma | 1 | 2017 | 17 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 347 | 0.140 |
Why?
| | Sarcoma, Ewing | 1 | 2017 | 65 | 0.140 |
Why?
| | Blotting, Western | 1 | 2019 | 1143 | 0.140 |
Why?
| | Heart Neoplasms | 1 | 2017 | 49 | 0.140 |
Why?
| | Immunophenotyping | 1 | 2017 | 274 | 0.130 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 57 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2017 | 149 | 0.130 |
Why?
| | Pyrimidines | 1 | 2019 | 374 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 184 | 0.130 |
Why?
| | Drug Synergism | 1 | 2017 | 315 | 0.130 |
Why?
| | Prognosis | 3 | 2019 | 3315 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2019 | 735 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2018 | 300 | 0.130 |
Why?
| | Flow Cytometry | 1 | 2019 | 1075 | 0.130 |
Why?
| | Signal Transduction | 2 | 2021 | 4501 | 0.130 |
Why?
| | Outpatients | 1 | 2019 | 325 | 0.130 |
Why?
| | Seizures | 1 | 2018 | 337 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2017 | 2173 | 0.120 |
Why?
| | Apoptosis | 3 | 2019 | 2349 | 0.120 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 521 | 0.120 |
Why?
| | Genetic Testing | 1 | 2017 | 381 | 0.120 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2014 | 37 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2021 | 12521 | 0.110 |
Why?
| | Female | 10 | 2021 | 59324 | 0.110 |
Why?
| | NF-kappa B | 1 | 2017 | 636 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 324 | 0.110 |
Why?
| | Brain Stem | 1 | 2014 | 94 | 0.110 |
Why?
| | Histones | 1 | 2018 | 529 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2017 | 591 | 0.110 |
Why?
| | MicroRNAs | 1 | 2019 | 600 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2017 | 9049 | 0.110 |
Why?
| | Cohort Studies | 2 | 2021 | 4883 | 0.100 |
Why?
| | Phenotype | 2 | 2024 | 2784 | 0.100 |
Why?
| | Glutamic Acid | 1 | 2014 | 210 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 157 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2015 | 673 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2017 | 754 | 0.090 |
Why?
| | Young Adult | 3 | 2021 | 10444 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 153 | 0.080 |
Why?
| | Hippocampus | 1 | 2014 | 690 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1145 | 0.080 |
Why?
| | Animals | 6 | 2021 | 31565 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2012 | 476 | 0.080 |
Why?
| | Neuropsychological Tests | 1 | 2012 | 926 | 0.070 |
Why?
| | Adult | 2 | 2019 | 30375 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6306 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3039 | 0.070 |
Why?
| | Neurons | 1 | 2014 | 1277 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1117 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2159 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 873 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2019 | 518 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1518 | 0.060 |
Why?
| | Gene Ontology | 1 | 2021 | 46 | 0.050 |
Why?
| | Autophagosomes | 1 | 2021 | 19 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 181 | 0.050 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 39 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 241 | 0.040 |
Why?
| | Lysosomes | 1 | 2021 | 123 | 0.040 |
Why?
| | Phosphorylation | 2 | 2015 | 1558 | 0.040 |
Why?
| | Aged | 1 | 2018 | 18969 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 405 | 0.040 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2019 | 27 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 104 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 71 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2019 | 151 | 0.040 |
Why?
| | Middle Aged | 1 | 2018 | 26605 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 990 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2018 | 131 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 229 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 122 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 339 | 0.040 |
Why?
| | DNA Methylation | 1 | 2021 | 493 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 307 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 14 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 541 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 46 | 0.030 |
Why?
| | Urea | 1 | 2016 | 66 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 175 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 723 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 108 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 337 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 262 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 618 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 81 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 5 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 9 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 13 | 0.030 |
Why?
| | Pepstatins | 1 | 2014 | 4 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 813 | 0.030 |
Why?
| | Sequestosome-1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2015 | 126 | 0.030 |
Why?
| | Pyrazoles | 1 | 2016 | 361 | 0.030 |
Why?
| | Leucine | 1 | 2014 | 102 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2014 | 112 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 170 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1131 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 2014 | 96 | 0.030 |
Why?
| | Tumor Burden | 1 | 2014 | 258 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1947 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 384 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 2014 | 171 | 0.030 |
Why?
| | Doxorubicin | 1 | 2014 | 286 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 628 | 0.030 |
Why?
| | Models, Biological | 1 | 2019 | 1611 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 503 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 475 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 431 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 534 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 399 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2014 | 777 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 695 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2090 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4392 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3397 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2322 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1356 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1016 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 1824 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 3861 | 0.020 |
Why?
| | Rats | 1 | 2014 | 4913 | 0.020 |
Why?
| | Mice | 1 | 2014 | 14843 | 0.010 |
Why?
|
|
Mulcahy Levy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|